The MIT-led projects will investigate novel high-performance designs, materials, processes, and assessment methods for an environmentally sustainable microchip industry.
Alnylam Pharmaceuticals, founded by MIT professors and former postdocs, has turned the promise of RNAi research into a new class of powerful therapies.